{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T14:40:01Z","timestamp":1756392001730,"version":"3.44.0"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T00:00:00Z","timestamp":1752278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T00:00:00Z","timestamp":1752278400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s10147-025-02830-1","type":"journal-article","created":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T03:00:01Z","timestamp":1752289201000},"page":"1679-1680","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; nivolumab plus ipilimumab for hepatocellular carcinoma, fedratinib for myelofibrosis, talquetamab for multiple myeloma, and belzutifan for tumors associated with von Hippel-Lindau disease and renal cell carcinoma"],"prefix":"10.1007","volume":"30","author":[{"given":"Noriomi","family":"Matsumura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Mandai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,12]]},"reference":[{"key":"2830_CR1","unstructured":"Pharmaceuticals and Medical Devices Agency (2025) List of approved drugs (in Japanese). https:\/\/www.pmda.go.jp\/review-services\/drug-reviews\/review-information\/p-drugs\/0010.html Accessed on June 30, 2025"},{"key":"2830_CR2","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1016\/S0140-6736(25)00403-9","volume":"405","author":"T Yau","year":"2025","unstructured":"Yau T, Galle PR, Decaens T et al (2025) Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial. Lancet 405:1851\u20131864. https:\/\/doi.org\/10.1016\/S0140-6736(25)00403-9","journal-title":"Lancet"},{"key":"2830_CR3","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1001\/jamaoncol.2015.1590","volume":"1","author":"A Pardanani","year":"2015","unstructured":"Pardanani A, Harrison C, Cortes JE et al (2015) Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial. JAMA Oncol 1:643\u2013651. https:\/\/doi.org\/10.1001\/jamaoncol.2015.1590","journal-title":"JAMA Oncol"},{"key":"2830_CR4","doi-asserted-by":"publisher","first-page":"e317","DOI":"10.1016\/S2352-3026(17)30088-1","volume":"4","author":"CN Harrison","year":"2017","unstructured":"Harrison CN, Schaap N, Vannucchi AM et al (2017) Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study. Lancet Haematol 4:e317\u2013e324. https:\/\/doi.org\/10.1016\/S2352-3026(17)30088-1","journal-title":"Lancet Haematol"},{"key":"2830_CR5","unstructured":"Bristol-Myers Squibb Company (2025) Package insert for Inrebic capsules. (in Japanese) https:\/\/www.info.pmda.go.jp\/go\/pack\/42910H8M1024_1_01\/?view=frame&style=XML&lang=ja Accessed on June 30, 2025"},{"key":"2830_CR6","doi-asserted-by":"publisher","first-page":"e269","DOI":"10.1016\/S2352-3026(24)00385-5","volume":"12","author":"A Chari","year":"2025","unstructured":"Chari A, Touzeau C, Schinke C et al (2025) Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1\u20132 study. Lancet Haematol 12:e269\u2013e281. https:\/\/doi.org\/10.1016\/S2352-3026(24)00385-5","journal-title":"Lancet Haematol"},{"key":"2830_CR7","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1056\/NEJMoa2103425","volume":"385","author":"E Jonasch","year":"2021","unstructured":"Jonasch E, Donskov F, Iliopoulos O et al (2021) Belzutifan for renal cell carcinoma in von Hippel-Lindau disease. N Engl J Med 385:2036\u20132046. https:\/\/doi.org\/10.1056\/NEJMoa2103425","journal-title":"N Engl J Med"},{"key":"2830_CR8","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1056\/NEJMoa2313906","volume":"391","author":"TK Choueiri","year":"2024","unstructured":"Choueiri TK, Powles T, Peltola K et al (2024) Belzutifan versus everolimus for advanced renal-cell carcinoma. N Engl J Med 391:710\u2013721. https:\/\/doi.org\/10.1056\/NEJMoa2313906","journal-title":"N Engl J Med"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02830-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-025-02830-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02830-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T14:06:41Z","timestamp":1756390001000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-025-02830-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,12]]},"references-count":8,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["2830"],"URL":"https:\/\/doi.org\/10.1007\/s10147-025-02830-1","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"type":"print","value":"1341-9625"},{"type":"electronic","value":"1437-7772"}],"subject":[],"published":{"date-parts":[[2025,7,12]]},"assertion":[{"value":"12 July 2025","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No author has any conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}